Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. Bedognetti D, et al. Among authors: samayoa j. J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y. J Immunother Cancer. 2019. PMID: 31272507 Free PMC article.
Immune oncology, immune responsiveness and the theory of everything.
Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J. Turan T, et al. Among authors: samayoa j. J Immunother Cancer. 2018 Jun 5;6(1):50. doi: 10.1186/s40425-018-0355-5. J Immunother Cancer. 2018. PMID: 29871670 Free PMC article.
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. Bedognetti D, et al. Among authors: samayoa j. J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. J Immunother Cancer. 2019. PMID: 31113486 Free PMC article. Review.
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response.
Roelands J, Hendrickx W, Zoppoli G, Mall R, Saad M, Halliwill K, Curigliano G, Rinchai D, Decock J, Delogu LG, Turan T, Samayoa J, Chouchane L, Ballestrero A, Wang E, Finetti P, Bertucci F, Miller LD, Galon J, Marincola FM, Kuppen PJK, Ceccarelli M, Bedognetti D. Roelands J, et al. Among authors: samayoa j. J Immunother Cancer. 2020 Apr;8(1):e000617. doi: 10.1136/jitc-2020-000617. J Immunother Cancer. 2020. PMID: 32376723 Free PMC article.
A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival.
Turan T, Kongpachith S, Halliwill K, Roelands J, Hendrickx W, Marincola FM, Hudson TJ, Jacob HJ, Bedognetti D, Samayoa J, Ceccarelli M. Turan T, et al. Among authors: samayoa j. Br J Cancer. 2021 Feb;124(4):760-769. doi: 10.1038/s41416-020-01145-4. Epub 2020 Nov 5. Br J Cancer. 2021. PMID: 33139798 Free PMC article.
Correction: A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival.
Turan T, Kongpachith S, Halliwill K, Roelands J, Hendrickx W, Marincola FM, Hudson TJ, Jacob HJ, Bedognetti D, Samayoa J, Ceccarelli M. Turan T, et al. Among authors: samayoa j. Br J Cancer. 2021 Mar;124(7):1340. doi: 10.1038/s41416-020-01193-w. Br J Cancer. 2021. PMID: 33277603 Free PMC article. No abstract available.
Cancer immune resistance: can theories converge?
Lu R, Turan T, Samayoa J, Marincola FM. Lu R, et al. Among authors: samayoa j. Emerg Top Life Sci. 2017 Dec 12;1(5):411-419. doi: 10.1042/ETLS20170060. Emerg Top Life Sci. 2017. PMID: 33525800 Free PMC article.
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R, Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S, Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT. Purcell JW, et al. Among authors: samayoa j. Cancer Res. 2018 Jul 15;78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. Epub 2018 May 15. Cancer Res. 2018. PMID: 29764866
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Ho SK, Xu Z, Thakur A, Fox M, Tan SS, DiGiammarino E, Zhou L, Sho M, Cairns B, Zhao V, Xiong M, Samayoa J, Forsyth CM, Powers DB, Chao DT, Hollenbaugh D, Alvarez HM, Akamatsu Y. Ho SK, et al. Among authors: samayoa j. Mol Cancer Ther. 2020 Apr;19(4):1040-1051. doi: 10.1158/1535-7163.MCT-19-0608. Epub 2020 Jan 23. Mol Cancer Ther. 2020. PMID: 31974274
25 results